← Back to Treatments
🏅 FDA Orphan Designation

IMLYGIC

talimogene laherparepvec

Manufacturer: BioVex, Inc. (subsidiary of Amgen)

Indicated for:
NON RARE IN EUROPE: MelanomaOrphan

FDA-Approved Indications (1)

Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery

Indications & Usage

1 INDICATIONS AND USAGE IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases. IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases. ( 1 )

💙 Support Programs

View all →
Imlygic
Amgen
Copay card ↗Apply ↗
IMLYGIC
BioVex, Inc. (subsidiary of Amgen)
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.